July 31, 2019 3-5PM ET
Wednesday on The Robert Scott Bell Show:
US measles outbreak helps boost Merck’s vaccine sales in second quarter Pharmaceutical giant Merck said Tuesday that high consumer demand for its measles vaccines, amid the largest U.S. outbreak in decades, helped boost sales in its second quarter. Sales of children’s vaccines, which includes the New Jersey-based company’s MMR vaccine, for measles, mumps and rubella, jumped 58% year over year to $675 million, Merck announced in its second-quarter earnings report Tuesday. Merck, which is the sole U.S. supplier of measles vaccines, said the strong growth was due in part to this year’s measles outbreak, which was the largest in the U.S. since 1992. “There was some buying to the private sector within the U.S. this quarter based on some of the measles outbreaks that you read in the news,” Merck Chief Commercial Officer Frank Clyburn said in a post-earnings conference call with investors. “And we do believe that we’ll continue to see growth for our pediatric vaccines going forward.”
Red flag upgrade for Pfizer: FDA limits Xeljanz in colitis, slaps black box on label For Pfizer’s blockbuster immunology drug Xeljanz, an FDA safety communication has now turned into a boxed warning. And forget the drug’s approval as a first-line ulcerative colitis treatment, at least for now. In a new addition to Xeljanz’s label on Friday, the FDA is warning of an increased risk of blood clots—and potentially, death—with the JAK inhibitor’s 10-mg twice daily dose. And meanwhile, the drug’s green light in ulcerative colitis has been pushed down the treatment line: It’s approved only for those who do not respond to or are not suitable for other medicines. While the cardiovascular risks showed up in rheumatoid arthritis patients taking the 10-mg dose in a postmarketing study, the FDA argued they “may also apply to those taking [Xeljanz] for ulcerative colitis.” The 10 mg dose is only approved in UC patients. Besides rheumatoid arthritis and colitis, Xeljanz’s 5-mg twice-daily dose is also approved in psoriatic arthritis.
Stomach-protecting medicines can trigger allergies Stomach-protecting drugs are widely used. Now, using quantitative prescribing data from Austria, a study conducted by MedUni Vienna in collaboration with the Austrian Social Insurance Institutions, has shown that stomach-protecting drugs (especially so-called proton pump inhibitors or PPIs) correlate with subsequent prescriptions for anti-allergy medication. Based on virtually the entire population, this now validates the finding of previous epidemiological and experimental studies that stomach-protecting drugs can intensify or even trigger allergies. The risk of an allergic reaction to allergens that requires anti-allergy treatment is doubled or even tripled. The results were recently published in Nature Communications. Gastric acid inhibitors reduce the production of gastric acid, relieve heartburn and promote healing of any damaged gastric mucosa. They are frequently prescribed in support of drug therapies to prevent stomach problems or to counteract bloating. They are often the drug of choice for stress responses leading to reflux (heartburn). In 2013, health insurers in Austria paid for prescriptions for at least one pack of PPIs for 1,540,505 people.
Hour 2 – Outside The Box With Ty Bollinger!
It’s time to go Outside The Box again with Ty Bollinger! What will we be talking about today?
Winners and losers from the first night of the CNN debate The first of two CNN-sponsored Democratic presidential debates is over. I watched — from the debate site in Detroit — and jotted down some of the best and worst performances from the 10 candidates on stage. My picks of the winners and losers from Tuesday night’s debate (in no particular order) are below.
California Passes Law Banning Trump from State Ballot Unless His Tax Returns Are Made Public We’re thrilled to see the far-left in America has the same respect for the Democratic process as their forebears did (for a reference to their forebears, see here). On Tuesday, Calif. Gov. Gavin Newsom signed a bill requiring President Trump to either release his tax returns or he won’t appear on the ballot in the state. Under SB 27, called the “Presidential Tax Transparency and Accountability Act,” any candidate running for president or governor in California must file copies of their tax returns from the previous five years to the California secretary of State, or their names will be stricken from the ballot, the Hill reports. Newsom argued that, as the largest economic engine within the US, California has a “responsibility” to demand this additional information (for the record: the Constitution doesn’t say anything about candidates releasing tax returns – though the federal income tax didn’t exist back on).
Surprising Survey Shows 45% of Americans Doubt Safety of Vaccines The latest measles outbreak that’s gripped communities across the country in recent months pushed the topic of vaccinations (and those who choose to forgo them) right back onto centerstage for many Americans. Now a new survey delving into feelings over immunizations finds the country may be more split on the issue than believed, with 45% of adults admitting to harboring some doubt about the safety of vaccines. That said, the vast majority — more than eight in 10 surveyed — still view vaccines as effective and continue to support them, despite their concerns. The survey, funded by the American Osteopathic Association, questioned 2,000 adults and asked doubters the source of their suspicions of the science-supported, long-established safety and importance of vaccinations. Of the nearly half who listed at least one source of doubt over vaccine safety, researchers found the most common sources came from online articles (16%), distrust of the pharmaceutical industry (16%), and information from medical experts (12%).
That meme you shared? It may soon cost you $15,000 Have you ever shared a meme that you didn’t make? Or downloaded a photo you saw on social media? If Congress has its way, you could soon get slapped with a $15,000 fine by copyright trolls––with no chance of appeal––just for doing normal stuff on the Internet. These trolls buy up copyrights with the sole intent of sending out mass threats and lawsuits to harvest settlements. Now, a dangerous new bill called the Copyright Alternative in Small Claims Enforcement (CASE) Act is sailing through Congress to make it easier for everyone from trolls to Hollywood producers to sue you. And it just slipped through a Senate Committee, clearing the way for a full Senate vote. In recent years, federal courts have made it easier for regular people to defend themselves from frivolous lawsuits by trolls. But the CASE Act would create a separate, industry-friendly system for copyright claims to $30,000, with no option of appeal. The corporate interests pushing this bill through Congress are the same ones that created the SOPA/PIPA.
Remember Friends, The Power to Heal is Yours!
More upcoming RSB events:
- The Truth About Cancer LIVE Oct 11-13 2019 Anaheim, CA
- Trinity Health Freedom Expo Oct 26-27 2019 Tinley Park, IL